



Trastuzumab emtansine

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

| | |
|--------------------|---|
| INN | Trastuzumab emtansine |
| ATC codes | L01FD03 |
| Medicine type | Biological agent |
| EML status history | Application rejected in 2017 (TRS 1006) for Carcinoma of breast, specialised type |
| Wikipedia | Trastuzumab emtansine  |
| DrugBank | Trastuzumab emtansine  |

Recommendations

Section Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

